Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Corver, Willem E ^a   Ruano, Dina ^a   Weijers, Karin ^a   den Hartog, Wietske C E ^a   van Nieuwenhuizen, Merlijn P ^a   de Miranda, Noel ^a   van Eijk, Ronald ^a   Middeldorp, Anneke ^a   Jordanova, Ekaterina S ^a   Oosting, Jan ^a   Kapiteijn, Ellen ^a   Hovens, Guido ^a   Smit, Jan ^a   van Wezel, Tom ^a   Morreau, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; AGED; ALLELE; ARTICLE; CHROMOSOME 22Q; CHROMOSOME 7; CLINICAL ARTICLE; DIPLOIDY; ENDOREDUPLICATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; HAPLOIDY; HETEROZYGOSITY; HETEROZYGOUS RETENTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONOSOMY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOCYTIC THYROID FOLLICULAR CARCINOMA; RECURRENT CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID FOLLICULAR CARCINOMA; BIOLOGICAL MODEL; COHORT ANALYSIS; DISEASE COURSE; GENETICS; HOMOZYGOTE; HUMAN GENOME; MIDDLE AGED; PATHOLOGY; PHENOTYPE; RECURRENT DISEASE; REPRODUCIBILITY; THYROID PARAFOLLICULAR CELL; THYROID TUMOR; TUMOR GENE;

AGED; AGED, 80 AND OVER; ALLELES; CHROMOSOMES, HUMAN, PAIR 7; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; GENES, NEOPLASM; GENOME, HUMAN; HAPLOIDY; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXYPHIL CELLS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; REPRODUCIBILITY OF RESULTS; THYROID NEOPLASMS;

EID: 84861719001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038287     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885-4893.
3. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, et al. (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA 104: 9001-9006.
4. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, et al. (1999) Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 79: 547-555.
5. Frisk T, Kytola S, Wallin G, Zedenius J, Larsson C, (1999) Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. Genes Chromosomes Cancer 25: 349-353.
6. Unger K, Malisch E, Thomas G, Braselmann H, Walch A, et al. (2008) Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Oncogene 27: 4592-4602.
7. Ribeiro FR, Meireles AM, Rocha AS, Teixeira MR, (2008) Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer 16: 371.
8. Gasparre G, Bonora E, Tallini G, Romeo G, (2010) Molecular features of thyroid oncocytic tumors. Mol Cell Endocrinol 321: 67-76.
9. Wada N, Duh QY, Miura D, Brunaud L, Wong MG, et al. (2002) Chromosomal aberrations by comparative genomic hybridization in hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin Endocrinol Metab 87: 4595-4601.
10. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA, (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63: 4561-4567.
11. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, et al. (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23: 1191-200.
12. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, et al. (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580.
13. Frattini M, Ferrario C, Bressan P, Balestra D, De CL, et al. (2004) Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23: 7436-7440.
14. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326.
15. Nikiforov YE, (2011) Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 135: 569-577.
16. Liu Z, Hou P, Ji M, Guan H, Studeman K, et al. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93: 3106-3116.
17. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW, et al. (2011) New treatment modalities in advanced thyroid cancer. Ann Oncol 23: 10-18.
18. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, et al. (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26: 4714-4719.
19. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, et al. (2009) Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161: 923-931.
20. Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, et al. (2005) High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues. J Pathol 206: 233-241.
21. Oosting J, Lips EH, van Eijk R, Eilers PH, Szuhai K, et al. (2007) High-resolution copy number analysis of paraffin-embedded archival tissue using SNP BeadArrays. Genome Res 17: 368-376.
22. Corver WE, Middeldorp A, Ter Haar NT, Jordanova ES, van PM, et al. (2008) Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations. Cancer Res 68: 10333-10340.
23. El-Naggar AK, Batsakis JG, Luna MA, Hickey RC, (1988) Hurthle cell tumors of the thyroid. A flow cytometric DNA analysis. Arch Otolaryngol Head Neck Surg 114: 520-521.
24. McLeod MK, Thompson NW, Hudson JL, Gaglio JA, Lloyd RV, et al. (1988) Flow cytometric measurements of nuclear DNA and ploidy analysis in Hurthle cell neoplasms of the thyroid. Arch Surg 123: 849-854.
25. Schultz DS, Zarbo RJ, (1992) Comparison of eight modifications of Hedley's method for flow cytometric DNA ploidy analysis of paraffin-embedded tissue. Am J Clin Pathol 98: 291-295.
26. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA, (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335.
27. Bovee JV, van RM, Bardoel AF, Rosenberg C, Cornelisse CJ, et al. (2000) Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. Am J Pathol 157: 1587-1595.
28. Gregori-Romero MA, Morell-Quadreny L, Llombart-Bosch A, (1996) A singular case of near-haploid stemline karyotype in a renal oncocytoma. Cancer Genet Cytogenet 92: 28-30.
29. Kim HJ, Shen SS, Ayala AG, Ro JY, Truong LD, et al. (2009) Virtual-karyotyping with SNP microarrays in morphologically challenging renal cell neoplasms: a practical and useful diagnostic modality. Am J Surg Pathol 33: 1276-1286.
30. Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, et al. (2009) High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 9: 152.
31. Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, et al. (2010) Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 10: 196.
32. Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, et al. (1998) Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin. Thyroid 8: 475-483.
33. Savagner F, Chevrollier A, Loiseau D, Morgan C, Reynier P, et al. (2001) Mitochondrial activity in XTC.UC1 cells derived from thyroid oncocytoma. Thyroid 11: 327-333.
34. Stankov K, Biondi A, D'Aurelio M, Gasparre G, Falasca A, et al. (2006) Mitochondrial activities of a cell line derived from thyroid Hurthle cell tumors. Thyroid 16: 325-331.
35. Rizzoni M, Palitti F, Perticone P, (1974) Euploid segregation through multipolar mitosis in mammalian cell cultures. Identification of triploid, haploid, and segregating diploid cells in a diploid-euploid primary culture of rhesus kidney cells. Chromosoma 45: 151-162.
36. Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, et al. (2001) Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 86: 4920-4925.
37. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, et al. (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA 104: 9001-9006.
38. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, et al. (2006) Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 66: 6087-6096.
39. Zimmermann FA, Mayr JA, Feichtinger R, Neureiter D, Lechner R, et al. (2011) Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors. Front Biosci (Elite Ed) 3: 315-325.
40. Nagy A, Wilhelm M, Sukosd F, Ljungberg B, Kovacs G, (2002) Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosomes Cancer 35: 256-260.
41. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, et al. (2008) Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 14: 2270-2275.
42. Speicher MR, Schoell B, du MS, Schrock E, Ried T, et al. (1994) Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145: 356-364.
43. Zedenius J, Wallin G, Svensson A, Grimelius L, Hoog A, et al. (1995) Allelotyping of follicular thyroid tumors. Hum Genet 96: 27-32.
44. Stankov K, Pastore A, Toschi L, McKay J, Lesueur F, et al. (2004) Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors. Int J Cancer 111: 463-467.
45. Tung WS, Shevlin DW, Kaleem Z, Tribune DJ, Wells SA Jr, et al. (1997) Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer 19: 43-51.
46. Dettori T, Frau DV, Lai ML, Mariotti S, Uccheddu A, et al. (2003) Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations. Genes Chromosomes Cancer 38: 22-31.
47. Masago K, Asato R, Fujita S, Hirano S, Tamura Y, et al. (2009) Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 124: 2744-2749.
48. Hogan T, Jing JY, Williams HJ, Altaha R, Xiaobing L, et al. (2009) Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract 15: 111-117.
49. Nikiforova MN, Nikiforov YE, (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8: 83-95.
50. Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, et al. (2011) Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab 96: E19-E30.